Trending menu:
Comment
-
30 January 2019
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges of patient recruitment
-
28 January 2019
Medical Device Development – Challenges of an SME
John Shillingford, Clinical Operations Director, Orsus Medical, describes the inherent challenges facing small- to mid-sized medical device companies
-
18 January 2019
Managing Blinding Requirements in IRT: An Overview
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded information in clinical trials
-
16 January 2019
Industry Viewpoints: Clinical Trials in Asia – Key Considerations
Mainfong Ang, Amgen, sits down with CTA’s Jisong Seo about the difficulties of clinical operations in Asia
-
14 January 2019
Integrating New Assets: A Supply Chain Perspective
Barrett Glasser, Associate Director, Clinical Drug Supply, Biogen, provides an overview on how to on board newly acquired therapeutic assets
-
11 January 2019
Observations from GCP Sponsor Inspections
Kevin Anderson, Director, Global Clinical Operations, Alexion Pharmaceuticals, offers a perspective on what he has observed in various GCP inspections
-
17 December 2018
Strategic Comparator Sourcing – A Matter of High Priority
Ian Hoban, Pilatus Comparator Solutions, poses some key questions that should be front of mind and considered early on in the design of your clinical trial
-
10 December 2018
How to Enable Greater Budget Forecasting
Ken Olovich, R.Ph., MBA, Sourcing and Financial Director of Chorus, Eli Lilly, explains a model of budget transparency with CROs to enable better budget forecasting
-
7 December 2018
The Dawn of Cell Therapies, Blockchain, and M&A: Industry Trends in the CMO Landscape
Peter Shapiro, Editor-In-Chief, PharmSource, a GlobalData Product, assesses key trends currently changing the face of the contract manufacturing industry
-
30 November 2018
The United Kingdom of Green Britain
As medicinal cannabis hits the U.K., CTA’s Harry Parsons takes a look at the ground-breaking reform taking place and how it could impact clinical research